Standard Biotools (LAB) Non Operating Interest Expenses (2010 - 2024)

Standard Biotools (LAB) has reported Non Operating Interest Expenses for 15 consecutive years, with $2.2 million the latest figure, recorded in Q1 2024.

• On a quarterly basis, Non Operating Interest Expenses rose 3686.44% year-over-year to $2.2 million in Q1 2024; TTM through Mar 2024 was $5.7 million, a 69.17% increase from a year earlier, with the FY2023 full-year figure at $4.6 million, up 5.45% from the prior year.
• Non Operating Interest Expenses was $2.2 million for Q1 2024 at Standard Biotools, up from $1.1 million in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $2.8 million in Q3 2021 and troughed at $59000.0 in Q1 2023.
• A 5-year average of $1.2 million and a median of $1.1 million in 2022 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses slumped 94.27% in 2023 and jumped 3686.44% in 2024, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $890000.0 in 2020, then surged by 209.1% to $2.8 million in 2021, then slumped by 56.74% to $1.2 million in 2022, then retreated by 7.73% to $1.1 million in 2023, then soared by 103.46% to $2.2 million in 2024.
• The last three Non Operating Interest Expenses figures came in at $2.2 million (Q1 2024), $1.1 million (Q4 2023), and $1.2 million (Q3 2023), per Business Quant data.